Cue Biopharma Inc (NASDAQ:CUE)’s traded shares stood at 1.33 million during the last session, with the company’s beta value hitting 1.72.The CUE share’s 52-week high remains $3.25, putting it -116.67% down since that peak but still an impressive 70.0% since price per share fell to its 52-week low of $0.45. The company has a valuation of $90.31M, with an average of 0.67 million shares in intraday trading volume over the past 10 days and average of 686.87K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Cue Biopharma Inc (CUE), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give CUE a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.19.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cue Biopharma Inc (NASDAQ:CUE) trade information
The 5-day price performance for the stock is -15.73%, and 40.19% over 30 days. With these gigs, the year-to-date price performance is -43.18%. Short interest in Cue Biopharma Inc (NASDAQ:CUE) saw shorts transact 1.78 million shares and set a 1.54 days time to cover.
The extremes give us $2 and $7 for target low and target high price respectively. As such, CUE has been trading -366.67% off suggested target high and -33.33% from its likely low.
Cue Biopharma Inc (CUE) estimates and forecasts
Looking at statistics comparing Cue Biopharma Inc share performance against respective industry, we note that the company has outperformed competitors. Cue Biopharma Inc (CUE) shares are -13.79% down over the last 6 months, with its year-to-date growth rate higher than industry average at 34.23% against 16.90%. Revenue is forecast to grow 20.83% this quarter before jumping 71.27% for the next one. The rating firms project that company’s revenue will grow 102.78% compared to the previous financial year.
Revenue forecast for the current quarter as set by 4 analysts is 1.52M. Meanwhile, for the current quarter, a total of 4 analyst(s) estimate revenue growth to 5.23M.Earnings reports from the last fiscal year show that sales brought in 2.1M and 1.82M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -27.64% before jumping 186.97% in the following quarter.
CUE Dividends
Cue Biopharma Inc has its next earnings report out in December. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Cue Biopharma Inc (NASDAQ:CUE)’s Major holders
Cue Biopharma Inc insiders hold 0.55% of total outstanding shares, with institutional holders owning 25.18% of the shares at 25.32% float percentage. In total, 25.18% institutions holds shares in the company, led by BLEICHROEDER LP. As of 2024-06-30, the company held over 2.86 million shares (or 5.7849% of shares), all amounting to roughly $3.55 million.
The next major institution holding the largest number of shares is SLATE PATH CAPITAL LP with 2.4 million shares, or about 4.8567% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $2.98 million.
